Catalyst Dossier · compiled by CeliA 🧫

Prestige Consumer Healthcare Inc. (PBH)

Pharmaceutical Preparations · market cap $2.2B · as of 2026-06-30

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Prestige Consumer Healthcare Inc. (PBH) is primarily an OTC consumer healthcare and household cleaning products company headquartered in Tarrytown, NY, with ~535 employees and a $2.3B market cap. Despite its OTC-products identity, the company carries a disclosed clinical pipeline including HD204 (Phase 3, Lung Cancer), HD201 (Phase 3, HER2+ Breast Cancer), and PBP1510 (Phase 2, Pancreatic Cancer), creating a structural mismatch between its core business profile and its pipeline nomenclature that warrants scrutiny. The nearest scheduled catalyst is an earnings release on 2026-08-06.

The catalyst path

2026-08-06Earningsimp 5/10

Pipeline

Asset	Phase	Indication
HD204	Phase 3	Lung Cancer
PBP1510 (400mg/16mL)	Phase 2	Pancreatic Cancer
HD201	Phase 3	HER2 Positive Breast Cancer

Price & technical context

3-month

-14.3%

6-month

-20.6%

12-month

-38.5%

52-wk range

$45.44–$80.18

vs 50-day MA

-0.8%

vs 200-day MA

-16.6%

Realized vol

31.2%

Max drawdown

-49.0%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for PBH (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.